The registry starts with a foundation of clinical data from more than 4.3 million patients with IBD or who have had screening colonoscopies, according to the release. The foundation of the AGA Registry is built from MedAssurant’s Medical Outcomes for Research on Economics and Effectiveness (MORE2) Registry.
The data in the registry allows for retrospective and prospective benchmarking, as well as a basis for immediate outcomes research, according to the release. Practices that participate in the registry will be able to run comparative reports after six months of data entry. The AGA Registry will also provide real-time feedback to practices about the care they provide, allowing them to compare outcomes with other physicians treating similar patients.
“The AGA Registry is a powerful tool that will help gastroenterologists improve quality of care by understanding what outcomes result from specific interventions,” Gail A. Hecht, MD, MS, AGAF, president of the AGA Institute, said in the release. “The registry is first and foremost a tool for quality improvement, but it will also support the business side of a medical practice. We plan for the registry to help physicians participate in commercial and government programs that provide incentives for quality measurement.”
The registry on IBD and CRC prevention is the first in a series, which will address the high-cost and high-variation aspects of care for patients with GI disease. The AGA Registry is available at www.AGARegistry.org.
Read the release on the AGA Registry.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.